Revolution Medicines (NASDAQ: RVMD) revenue
Revolution Medicines reported revenue of $0.0m for fiscal 2025; in fiscal 2024 it was $0.0m.
Revolution Medicines's best year of the last 7 was fiscal 2019. The biggest drop was in fiscal 2023, −67.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $0.0m | — | −$1,182m | — |
| 2024 | $0.0m | −100.0% | −$689.5m | — |
| 2023 | $11.6m | −67.3% | −$487.2m | −4,207.1% |
| 2022 | $35.4m | +20.4% | −$258.3m | −730.0% |
| 2021 | $29.4m | −31.6% | −$188.0m | −639.7% |
| 2020 | $43.0m | −14.1% | −$110.7m | −257.5% |
| 2019 | $50.0m | — | −$54.1m | −108.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Revolution Medicines revenue compared with its sector
By revenue for its latest fiscal year, Revolution Medicines ranks 416th of the 422 US health care companies with a page on Celsmar.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 414th | Praxis Precision Medicines | $0.0m | −100.0% |
| 415th | Rocket Pharmaceuticals | $0.0m | — |
| 416th | Revolution Medicines | $0.0m | — |
| 417th | SAB Biotherapeutics | $0.0m | −100.0% |
| 418th | Spruce Biosciences | $0.0m | −100.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Revolution Medicines
- How much revenue did Revolution Medicines make in fiscal 2025?
- Revolution Medicines reported revenue of $0.0m for fiscal 2025, compared with $0.0m in fiscal 2024.
- What was the best year for revenue at Revolution Medicines?
- Of its last 7 fiscal years, fiscal 2019, with $50.0m.
- Where does Revolution Medicines rank in its sector by revenue?
- It ranks 416th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Revolution Medicines come from?
- From the annual report (Form 10-K) that Revolution Medicines files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Revolution Medicines files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Revolution Medicines: the Revolution Medicines page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.